Cyclerion Therapeutics Inc. (CYCN) NASDAQ

$1.76 -0.21 (-10.66%)

Market Cap: $85.33M

As of 12/03/21 03:59 PM EST. Market closed.

(CYCN)

Cyclerion Therapeutics Inc. (CYCN) NASDAQ

$1.76 -0.21 (-10.66%)

Market Cap: $85.33M

As of 12/03/21 03:59 PM EST. Market closed.

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion's lead program is CY6463, a novel, first-in-class, CNS-penetrant, sGC stimulator that modulates a key node in a fundamental CNS signaling network. The multidimensional pharmacology elicited by the stimulation of sGC has the potential to impact a broad ... read more

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion's lead program is CY6463, a novel, first-in-class, CNS-penetrant, sGC stimulator that modulates a key node in a fundamental CNS signaling network. The multidimensional pharmacology elicited by the stimulation of sGC has the potential to impact a broad range of CNS diseases. CY6463 has shown rapid improvement in biomarkers associated with cognitive impairment and is currently in clinical development for Alzheimer's Disease with Vascular pathology (ADv) and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS). read less

COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
CEO Compensation (Base)
$100,000
CEO Compensation (Total)
$5.16M
URL
Address
.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Full Time Employees
51
CEO Compensation (Base)
$100,000
CEO Compensation (Total)
$5.16M
Address
.
KEY STATS
Open
$1.87
Previous Close
$1.97
Days Range
$1.83 - $2.01
52 week range
$1.83 - $6.90
Volume
326,884
Avg. Volume (30 days)
541,346
Market Cap
$85.33M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
43,315,745
Open
$1.87
Previous Close
$1.97
Days Range
$1.83 - $2.01
52 week range
$1.83 - $6.90
Volume
326,884
Avg. Volume (30 days)
541,346
Market Cap
$85.33M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
43,315,745

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR CYCLERION THERAPEUTICS INC
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
MCGUIRE TERRANCE Director Jun 03, 2021 Buy $3.12 3,322 10,365 24,957 Jun 07, 2021, 05:36 PM
MCGUIRE TERRANCE Director Jun 03, 2021 Buy $3.12 92,831 289,633 697,313 Jun 07, 2021, 05:36 PM
Hecht Peter M Chief Executive Officer Jun 03, 2021 Buy $3.28 823,170 2,699,998 2,047,698 Jun 07, 2021, 05:25 PM
Hecht Peter M Chief Executive Officer May 06, 2021 Buy $2.43 302,000 733,860 1,224,528 May 10, 2021, 08:45 AM
Hecht Peter M Chief Executive Officer May 05, 2021 Buy $2.53 398,001 1,006,943 922,528 May 06, 2021, 09:27 PM
Hecht Peter M Chief Executive Officer May 04, 2021 Buy $2.29 300,000 687,000 524,527 May 06, 2021, 09:27 PM
Gjino Anjeza Chief Financial Officer Feb 25, 2021 Sale $4.00 1,824 7,296 31,599 Mar 01, 2021, 04:23 PM
Wright Christopher I Chief Medical Officer Feb 25, 2021 Sale $3.99 2,637 10,522 42,728 Mar 01, 2021, 12:00 AM
Currie Mark G President and CSO Dec 28, 2020 Sale $3.01 20,107 60,522 251,648 Dec 30, 2020, 01:14 PM
Busch Andreas Chief Innovation Officer Nov 09, 2020 Buy $2.53 125,000 316,250 254,704 Nov 12, 2020, 05:05 PM
Huyett William Chief Financial Officer Nov 06, 2020 Sale $2.52 3,827 9,644 67,590 Nov 10, 2020, 07:07 PM
Huyett William Chief Financial Officer Feb 21, 2020 Sale $5.12 3,559 18,222 71,417 Feb 25, 2020, 04:11 PM
Currie Mark G President Dec 30, 2019 Sale $2.48 25,000 62,000 271,755 Dec 31, 2019, 05:55 PM
Currie Mark G President Dec 27, 2019 Sale $2.55 25,000 63,750 296,755 Dec 31, 2019, 05:55 PM
Busch Andreas Chief Innovation Officer Nov 15, 2019 Buy $1.82 125,000 227,500 125,000 Nov 19, 2019, 04:02 PM
Huyett William Chief Financial Officer Nov 08, 2019 Sale $2.05 3,922 8,040 74,976 Nov 12, 2019, 04:26 PM
Hecht Peter M Chief Executive Officer Jul 10, 2019 Option Exercise $6.04 2,000 12,080 225,192 Jul 12, 2019, 04:09 PM
MCGUIRE TERRANCE Director Apr 08, 2019 Buy $16.00 21,635 346,160 21,635 Apr 10, 2019, 04:14 PM
MCGUIRE TERRANCE Director Apr 08, 2019 Buy $16.00 604,482 9,671,712 604,482 Apr 10, 2019, 04:14 PM
SCHULMAN AMY W Director Apr 08, 2019 Buy $16.00 21,635 346,160 21,635 Apr 10, 2019, 04:13 PM
SCHULMAN AMY W Director Apr 08, 2019 Buy $16.00 604,482 9,671,712 604,482 Apr 10, 2019, 04:13 PM
Currie Mark G President Apr 02, 2019 Buy $14.81 270,107 4,000,285 321,755 Apr 03, 2019, 07:42 PM
Load More Insider Transactions
Buy Sale Option Exercise
Owner Relationship Date Value($)
MCGUIRE TERRANCE Director 06/03/2021 10,365
MCGUIRE TERRANCE Director 06/03/2021 289,633
Hecht Peter M Chief Executive Officer 06/03/2021 2,699,998
Hecht Peter M Chief Executive Officer 05/06/2021 733,860
Hecht Peter M Chief Executive Officer 05/05/2021 1,006,943
Hecht Peter M Chief Executive Officer 05/04/2021 687,000
Gjino Anjeza Chief Financial Officer 02/25/2021 7,296
Wright Christopher I Chief Medical Officer 02/25/2021 10,522
Currie Mark G President and CSO 12/28/2020 60,522
Busch Andreas Chief Innovation Officer 11/09/2020 316,250
Huyett William Chief Financial Officer 11/06/2020 9,644
Huyett William Chief Financial Officer 02/21/2020 18,222
Currie Mark G President 12/30/2019 62,000
Currie Mark G President 12/27/2019 63,750
Busch Andreas Chief Innovation Officer 11/15/2019 227,500
Huyett William Chief Financial Officer 11/08/2019 8,040
Hecht Peter M Chief Executive Officer 07/10/2019 12,080
MCGUIRE TERRANCE Director 04/08/2019 346,160
MCGUIRE TERRANCE Director 04/08/2019 9,671,712
SCHULMAN AMY W Director 04/08/2019 346,160
SCHULMAN AMY W Director 04/08/2019 9,671,712
Currie Mark G President 04/02/2019 4,000,285
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
09/30/2021
09/30/2020
29.23%
4Q
09/30/2021
06/30/2020
36.06%
5Q

Period of Report: 09/30/2021

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2020
29.23%
4Q
06/30/2020
36.06%
5Q